At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
TachoSildrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Pilot Study With TachoSil as a Ventricular Sealant
In Brief
An observational study evaluating TachoSil for Intraventricular Neoplasm. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The working hypothesis in this study is that after entering the cerebral ventricular system the sealing with TachoSil is effective and safe. A more specific hypothesis is that the use of Tachosil for brain surgery with ventricular entry reduces the number of postoperative complications (hydrocephalus, CSF leak, meningitis and pseudomeningocele).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIntraventricular Neoplasm
CountriesSpain
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
Enrollment StartMay 2022
Primary CompletionFeb 2023
First PostedFeb 2023
TodayJul 2026
First PostedFeb 8, 2023
Enrollment StartMay 1, 2022
Primary CompletionFeb 3, 2023
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 3.4 years ago
Interventions
TachoSildrug
Placement of TachoSil over the ventricular entry point in patients with periventricular lesions in order to avoid complications related to the ventricular entry.